Crescita Expands Medical Aesthetic Portfolio with MicronJetTM600 The World’s Smallest Intradermal Delivery Device
Crescita Completes Acquisition of Strategic Assets of Occy Laboratory
Crescita to Acquire Strategic Assets of Occy Laboratory
Crescita Reports First Quarter 2024 Results
Crescita Reports Third Quarter 2023 Results
LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”) announced today that the Toronto Stock Exchange (the “TSX”) has approved the Company’s proposed normal course issuer bid (“NCIB”) to purchase up to a maximum of 1,821,616 common shares (“Common Shares”) for cancellation, representing approximately 10% of its public float as of August 18, 2023, as appropriate opportunities arise from time to time. As of August 27, 2023, the Company had 20,374,153 issued and outstanding Common Shares.
LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced the voting results from its Annual General and Special Meeting of Shareholders held at its corporate headquarters in Laval, Quebec on June 20, 2023. The detailed results of the votes received by proxy are as follows:
LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the first quarter ended March 31, 2023 (“Q1-F2023”). All amounts presented are in thousands of Canadian dollars (“CAD”) unless otherwise noted.
Crescita Reports Q4 and Fiscal 2022 Results
Crescita Reports Third Quarter 2022 Results